American International Group, Inc. Atreca, Inc. Transaction History

American International Group, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.56 - $3.25 $20,117 - $41,912	-12,896 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.61 - $5.2 $1,461 - $4,721	-908 Reduced 6.58%	12,896 $41,000
Q4 2021 Feb 11, 2022	SELL	$2.87 - $6.29 $1,182 - $2,591	-412 Reduced 2.9%	13,804 $42,000
Q3 2021 Nov 12, 2021	SELL	$4.91 - $9.07 $1,659 - $3,065	-338 Reduced 2.32%	14,216 $89,000
Q2 2021 Aug 13, 2021	SELL	$7.82 - $13.8 $17,485 - $30,856	-2,236 Reduced 13.32%	14,554 $124,000
Q1 2021 May 07, 2021	BUY	$13.0 - $19.34 $585 - $870	45 Added 0.27%	16,790 $257,000
Q4 2020 Feb 12, 2021	SELL	$13.03 - $17.09 $1,198 - $1,572	-92 Reduced 0.55%	16,745 $270,000
Q3 2020 Nov 04, 2020	BUY	$12.67 - $23.19 $48,462 - $88,701	3,825 Added 29.4%	16,837 $235,000
Q2 2020 Aug 12, 2020	BUY	$12.52 - $23.45 $35,193 - $65,917	2,811 Added 27.56%	13,012 $277,000
Q1 2020 May 04, 2020	BUY	$11.4 - $27.28 $69,825 - $167,090	6,125 Added 150.27%	10,201 $169,000
Q4 2019 Feb 05, 2020	SELL	$9.68 - $18.67 $338 - $653	-35 Reduced 0.85%	4,076 $63,000
Q3 2019 Nov 08, 2019	BUY	$10.42 - $22.04 $42,836 - $90,606	4,111 New	4,111 $50,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.